Daratumumab injection (intravenous) | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
Others
- Brand
- Darzalex
- Company
- Janssen Biotech, Inc.
- Medicine type
- Biologic
- Therapeutic area
- Oncology
- Indications recorded in the public source
- US use in adult multiple myeloma includes specified multidrug regimens for newly diagnosed or previously treated disease, selected according to transplant eligibility and treatment history. Examples include lenalidomide plus dexamethasone for newly diagnosed transplant-ineligible patients or relapsed/refractory patients after at least one prior therapy. Monotherapy requires at least three prior lines including a proteasome inhibitor and an immunomodulatory agent, or resistance to both classes. The linked label gives the other approved combinations.
- Indication source and scope
- US prescribing information revised June 2026. Selected overseas indications; does not establish the Chinese approved scope.
- Prescribing-information limitations
- Overseas official prescribing information linked; a complete current Chinese label has not been verified.
- China availability status
- Chinese approval details and current availability have not been independently verified in this English-source review.
- Overseas status
- See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
- Insurance classification
- Not yet verified
- Insurance edition
- Chinese national insurance review pending
- Insurance verification notes
- No reimbursement determination was made for this addition; missing information is not proof of exclusion.
Sources
- https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf
- Darzalex — US prescribing information
Official prescribing information · US prescribing information revised June 2026
English primary source opened on 2 November 2026. The summary lists selected US indications, not the complete current Chinese approved scope.
- FDA NDC directory — packaging reference
Supplied report reference · Report dated 25 October 2026
Original report citation retained for traceability. This citation alone does not verify Chinese approval, brand identity, equivalent formulations or like-for-like prices. WAC unit and pack conversions require separate confirmation.
- Texas DSHS — 2026 annual WAC report
Supplied report reference · Report dated 25 October 2026
Original report citation retained for traceability. This citation alone does not verify Chinese approval, brand identity, equivalent formulations or like-for-like prices. WAC unit and pack conversions require separate confirmation.
- Shenzhen New Frontier United Family Hospital — public prices
Supplied report reference · Report dated 25 October 2026
Original report citation retained for traceability. This citation alone does not verify Chinese approval, brand identity, equivalent formulations or like-for-like prices. WAC unit and pack conversions require separate confirmation.
Evidence reviewed:
Open the interactive record, public price references and discussions